Sumit Ahuja

AI, longevity, and the long future of humanity.

[Sumit Ahuja @Sumit_A]

https://t.co/v9GDa7gIqV

[Sumit Ahuja @Sumit_A]

The first human dose of ER-100 (@davidasinclair, @lifebiosciences). A real breakthrough out of VERVE-102. @chamath weighing in. @hubermanlab dropping a peptide masterclass.

Longevity just became the loudest conversation in the room. If you are only now tuning in, it is a lot, and most people have no idea where to start.

I do. So I am going to take you there.

This is the first in a series that gets the rest of us from lost to fluent. I will break down the science, the chemistry, and the biological pathways, in plain language and in the right order.

Start here.

[Sumit Ahuja @Sumit_A]

https://t.co/v9GDa7gIqV

[Sumit Ahuja @Sumit_A]

@bryan_johnson Fire whoever suggested you CJC w/DAC. You didn't try CJC-1295, you tried a modified variant with wrong PK profile, and predictable metabolic fallout. CJC-1295 w/ DAC is not how serious practitioners approach GH modulation. This outcome was avoidable.

CJC-1295 with DAC has fundamentally different pharmacokinetics vs non-DAC GHRH analogs, you’re forcing prolonged GH elevation instead of pulsatile signaling. That breaks the physiology.

+ fasting glucose, + C-peptide, + insulin resistance: classic GH overexposure pattern.

- REM sleep: CNS disruption from non-physiologic GH rhythm.

Flat IGF-1 response: poor downstream signaling despite GH spike.

This is documented. DAC was a pharma-driven modification to extend half-life. Most experienced clinicians avoid it entirely for this reason.

You didn’t really test “a peptide.”
You tested a modified version with known tradeoffs that distort the intended pathway.

Correct approach would involve:
Pulsatile GH optimization (not continuous elevation)
Proper dosing + cycling strategy
Contextual and intelligent stacking

Over the years, I’ve trained 30+ physicians on peptide pathways, dosing, cycling, and stacking; happy to consult.

[Sumit Ahuja @Sumit_A]

@bryan_johnson You did the wrong CJC. Who’s advising you?!

[Sumit Ahuja @Sumit_A]

@MattPRD @moltbook https://t.co/5MJzh37HCy - We provide human intent and behavioral signals to @openclaw bots for personalized and precise agentic decisions.

[Sumit Ahuja @Sumit_A]

We are. CGMP & FDA Inspected USA based manufacturing. Not only that, but onboarded MIT PHD Scientists to formulate unique blends, conjugations and modifications to revolutionize the entire industry.

Very close to closing pre-seed. Deck and data-room immediately available.

Sumit at maintherapeutics com

[Sumit Ahuja @Sumit_A]

@SherryYanJiang Nailed it. Intent is everything.

https://t.co/5MJzh38fs6

[Sumit Ahuja @Sumit_A]

@signulll We are on it and privacy-first.

https://t.co/5MJzh38fs6

[Sumit Ahuja @Sumit_A]

@0xDevShah On it and in full effect.

https://t.co/5MJzh38fs6

[Sumit Ahuja @Sumit_A]

This is not just a play on content, it’s an indirect play on “intent”. Short-form feeds become a live stream of human behavior: attention, preference, emotion. This stream powers intent fort all of agentic commerce.

The model stops training on culture and starts learning inside it. Building at https://t.co/UgNKXeda3J.

[Sumit Ahuja @Sumit_A]

@alex_prompter Most “agentic AI” systems do not fail because they lack intelligence.
They fail because they lack adaptation.

The research highlights the real gap.
Adaptation is not fine-tuning or retraining.
It is online monitoring, failure detection, and mid-task policy revision.

This is why memory outperforms raw reasoning.
Storing structured outcome data and corrective deltas enables faster adaptation than longer chains of thought.

@MainLabs_AI Human Intent Network is designed around this missing layer.
Real-time human feedback as a control signal.
Persistent short-horizon learning memory.
Dynamic tool re-ranking and abandonment.
Continuous inference of intent rather than static goals.

Scaling agentic systems is not about larger models.
It is about closed-loop architectures that can detect divergence and adapt in real time.

Without adaptation, autonomy is just automation with confidence.

[Sumit Ahuja @Sumit_A]

@th3_real_mars @maxmarchione Not for sale bud, just evaluations.

[Sumit Ahuja @Sumit_A]

@iBinaryEngineer @maxmarchione Guilty. Been too busy building to broadcast. Might have to pivot to influencer mode soon.

[Sumit Ahuja @Sumit_A]

@iBinaryEngineer @maxmarchione Appreciate it, but that bio’s outdated. fr. Wait till you see the next few chapters.

[Sumit Ahuja @Sumit_A]

@shroom_daddy @maxmarchione It's not that cheap when you manufacture it in the U.S at a CGMP and FDA Approved facility.

[Sumit Ahuja @Sumit_A]

@Big_Pharmai @maxmarchione Let's research together.

[Sumit Ahuja @Sumit_A]

@RegenRandy @maxmarchione These are samples from various manufacturers on their manufacturing abilities. COA's on hand.

[Sumit Ahuja @Sumit_A]

@th3_real_mars @maxmarchione you are not wrong, you are not right; certified manufacturing exceeds $15k. Retail price via RUO sites in the U.S exceeds $200k. High concentration/vial and you cannot see all of the stacks.

[Sumit Ahuja @Sumit_A]

@RyutaroWongso @maxmarchione @bryan_johnson He made a classic rookie move; he jumped straight to HGH, which is like bypassing the engine and pouring fuel on the hood. GHRH/GHRP (peptides) is the body's ignition switch. Always let endogenous systems take the first swing before calling in the heavy hitters.

[Sumit Ahuja @Sumit_A]

@Aboundlessworld @maxmarchione Legally obligated. Spiritually committed. 🔬